Pictet Bank Sells Major Stake in Merck & Co. Amid Portfolio Adjustments

PICTET BANK & TRUST Ltd has significantly reduced its stake in Merck & Co., Inc. (NYSE: MRK) by 78.3% during the third quarter of 2023. According to a recent filing with the U.S. Securities and Exchange Commission (SEC), the bank now holds 3,040 shares, down from 14,013 shares after selling 10,973 shares during the period. The remaining shares valued approximately $255,000 at the end of September.

Other institutional investors have also made notable adjustments to their holdings in Merck. Brighton Jones LLC increased its stake by 29.5% in the fourth quarter, owning 38,278 shares worth $3.8 million after acquiring an additional 8,710 shares. Additionally, Ancora Advisors LLC raised its holdings by 2.5%, bringing its total to 28,804 shares valued at $2.585 million following a purchase of 703 shares.

Curi RMB Capital LLC made a more substantial increase, raising its holdings in Merck by 54.1% and now owns 326,801 shares worth approximately $29.54 million. Similarly, Edmond DE Rothschild Holding S.A. and Hancock Whitney Corp also boosted their positions in the company during the first quarter.

As of now, approximately 76.07% of Merck’s stock is owned by hedge funds and other institutional investors, reflecting a significant interest in the pharmaceutical giant.

Stock Performance and Dividend Increase

On the stock market, Merck & Co., Inc. opened at $105.20 on Friday. The company has seen a fifty-day moving average of $96.98 and a two-hundred-day moving average of $87.76. Over the past year, the stock reached a low of $73.31 and a high of $107.59. The company’s market capitalization stands at $261.11 billion, with a price-to-earnings (P/E) ratio of 13.90 and a beta of 0.29.

Merck recently announced an increase in its quarterly dividend, set to be paid on January 8, 2024. Shareholders on record as of December 15, 2023 will receive a dividend of $0.85, up from the previous amount of $0.81. This adjustment represents an annualized dividend of $3.40, yielding 3.2%. The company’s payout ratio is currently at 44.91%.

Analyst Ratings and Insider Transactions

Recent analyst activity has been mixed regarding Merck shares. Scotiabank raised its price target from $105.00 to $120.00, assigning the stock a “sector outperform” rating. Conversely, Citigroup initiated coverage with a “neutral” rating and a target price of $95.00. Other analysts, including Bank of America and Deutsche Bank, have also adjusted their price objectives, with Bank of America setting a target of $120.00 and Deutsche Bank at $111.00.

Overall, eight analysts rated Merck with a “Buy” rating, while eight others issued a “Hold” rating and one analyst suggested a “Sell” rating. According to data from MarketBeat, the average rating for the stock remains at “Hold” with a consensus target price of $110.13.

In relation to insider transactions, Executive Vice President David Michael Williams sold 8,614 shares on November 3, 2023, at an average price of $83.59, totaling approximately $720,044. Following this transaction, Williams retained 24,578 shares valued at around $2.05 million, reflecting a 25.95% decrease in his ownership.

Merck & Co., Inc. is a global biopharmaceutical company focused on the discovery, development, manufacture, and marketing of prescription medicines, vaccines, and biologic therapies. The firm is particularly renowned for its oncology products and vaccines, including the immunotherapy Keytruda and the Gardasil vaccine.

As the company continues to navigate market dynamics and adjust its strategies, the recent changes in institutional holdings and analyst ratings signal the ongoing evaluation of its performance and future prospects in the biopharmaceutical sector.